January 30, 2012

The Food and Drug Administration has approved a long-acting injected diabetes drug made by Amylin Pharmaceuticals and Alkermes, the two companies said.

January 11, 2012

A special focus on its diabetes franchise will define Amylin Pharmaceuticals' corporate strategy, the company's chief executive said at a recent conference sponsored by J.P. Morgan.

December 8, 2011

A drug currently under clinical development for Type 2 diabetes produced "meaningful" reductions in blood sugar, according to results of a late-stage clinical study.

October 14, 2011

Two classes of drugs for treating Type 2 diabetes will experience the biggest growth in market share of all classes of drugs for the condition, according to a new study by Decision Resources.

October 11, 2011

The recent film “Contagion” depicts the world descending to chaos due to the spread of an extremely deadly virus. But in reality, one of the most serious epidemics doesn’t come from an infectious agent but from people’s life choices.


September 16, 2011

A drug made by Boehringer Ingelheim and Eli Lilly showed "meaningful and durable" reductions in blood sugar in adults with Type 2 diabetes, according to results of a late-stage clinical trial presented Friday at a conference in Europe.

September 13, 2011

An insulin analogue made by Sanofi appears to work better in certain cases than competing treatments at reducing weight gain and controlling blood sugar among patients with Type 2 diabetes.

September 12, 2011

Patients treated with a long-acting drug for Type 2 diabetes experienced a reduction in cardiovascular health risk factors, according to results of a study presented at the European Association for the Study of Diabetes' annual meeting.

September 8, 2011

Boehringer Ingelheim and Eli Lilly will present data from their diabetes portfolio at the 47th Annual Meeting of the European Association for the Study of Diabetes in Lisbon, Portugal.

August 8, 2011

Boston Therapeutics is seeking approval for a generic version of a pill for Type 2 diabetes, the drug maker said.

July 29, 2011

The Food and Drug Administration has approved a generic drug for diabetes made by Indian generic drug maker Strides Arcolab.

July 6, 2011

A once-monthly formulation of a drug made by Amylin Pharmaceuticals, Eli Lilly and Alkermes improved glucose control in patients with Type 2 diabetes, according to results of a mid-stage clinical trial presented at the American Diabetes Association’s 71st Scientific Sessions.

June 29, 2011

Adding an investigational drug for Type 2 diabetes to the common generic drug metformin helped control blood sugar in patients who could not control their blood sugar with metformin alone, according to results of a late-stage clinical study.

June 28, 2011

A cobranded Type 2 diabetes treatment may help reduce blood-sugar levels among patients when combined with insulin (with or without metformin), according to a late-stage clinical trial.

June 27, 2011

Use of a drug for Type 2 diabetes made by Eli Lilly and Amylin Pharmaceuticals may lower patients’ risk of heart failure, according to a new study.

June 27, 2011

An insulin product made by Eli Lilly appears likely to be more cost-effective than long-acting insulin analog, according to a study presented Friday at the American Diabetes Association’s 71st Scientific Sessions in San Diego.

June 20, 2011

Last month, the Food and Drug Administration approved Tradjenta (linagliptin), an oral Type 2 diabetes drug made by German drug maker Boehringer Ingelheim and Indianapolis-based Eli Lilly. The drug belongs to the class known as dipeptidyl peptidase-4 inhibitors, which also includes Merck’s Januvia (sitagliptin). With diabetes affecting some 26 million Americans and growing rapidly, Drug Store News spoke with Wa’el Hashad, BI’s VP cardiovascular and metabolic disorders marketing, about what the approval of Tradjenta means for the diabetes market.


June 17, 2011

A popular Type 2 diabetes treatment may help Type 1 diabetics achieve control of their blood-glucose levels, according to a small, observational study conducted at the University of Buffalo.

May 26, 2011

Eli Lilly is temporarily barred from using the same sales team to market two diabetes drugs, under a court order issued Thursday.

May 19, 2011

A controversial GlaxoSmithKline drug for treating Type 2 diabetes no longer will be available through retail pharmacies as of Nov. 18, the Food and Drug Administration announced Wednesday.

April 25, 2011

You can’t be all things to all people, but you can be all things to one person. That’s the opportunity Giant Eagle is grabbing with the number of ways the Pittsburgh food-and-pharmacy retailer interacts with patients. 


“Our goal is to help those within our communities live healthier, longer lives,” Dan Donovan, Giant Eagle spokesman, told Drug Store News. “We look to do this in a number of ways … [through] initiatives, such as our health and beauty care business, in-store retail health clinics and our group of skilled dietitians.”


April 12, 2011

A point-of-sale safety check may reduce the risk of patients unsafely receiving a drug for Type 2 diabetes that may increase their risk of heart attack, according to a new study conducted by pharmacy benefit manager Prime Therapeutics and scheduled for presentation at the 23rd annual meeting of the Academy of Managed Care Pharmacy in Minneapolis.

March 25, 2011

A drug for Type 2 diabetes made by Takeda Pharmaceutical taken in the morning prevented the disease from developing in nearly three-quarters of patients who were at risk, according to a new study in the New England Journal of Medicine.

March 18, 2011

With respect to the Type 2 diabetes drug Avandia, British drug maker GlaxoSmithKline has another medical study to worry about.